Real World Evidence

Skip To Main Content

This website is intended exclusively for healthcare professionals residing and/or working in Bahrain.

Campus

Login
Registration

Science
Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
Asthma
Chronic Obstructive Pulmonary Disease
Eosinophilic-Esophagitis
Multiple Myeloma
Nasal Polyps
Neurological Disorders
Prurigo-Nodularis
Rare Diseases

Atopic Dermatitis

Cutting Edge Science
Innovation

Cardiovascular
Atherothrombosis
Dyslipidemia
Hypertension
Thrombosis

Diabetes
Cutting Edge Science

Multiple Sclerosis

Cutting Edge Science
Innovation
2024
2025

Vaccines
Influenza
RSV
Mass Gathering

Patient Support
Atopic Dermatitis
Cardiovascular
Diabetes
Rare Diseases

Products
Adacel®
Cerezyme®
Lemtrada®
Myozyme®
Renvela®
Tavanic®
Xatral®

Aubagio®
Aubagio vs Ofatumumab

Beyfortus®
International Recommendation
Conferences
Real World Evidence
Clinical Experience

Clexane®
Surgical Patients
Hemodialysis

Dupixent®
Atopic Dermatitis

Fabrazyme®
Quantifying the Effect of Fabrazyme
Canadian Fabry Disease Initiative
Long Term Renal Function

Plavix®
Tolerability

Praluent®

It’s Praluent of Course
MACE Reduction
Mortality Reduction
Patient Friendly
Ticks All the Boxes

Soliqua®
For a Peaceful Ramadan
Soli-Simplify Study
Soliqua SoliD®
Soliqua Easy Start®
Soliqua Guidelines®
Soliqua Data Set®
Soliqua Simplicity®
Soliqua Safety®
Soliqua®

Toujeo®
Toujeo for a Peaceful Ramadan
Wall of Evidence
How to Start

Toujeo T1DM
OneCare
Edition Junior
UltraFlexi-1
Type-1 Meta Analysis
Guidelines

Toujeo T2DM
Deliver-G
Guidelines

Toujeo Innovation
Toujeo Upgrade to Win

Campus

Science
Acquired Thrombotic Thrombocytopenic Purpura (ATTP)
Asthma
Chronic Obstructive Pulmonary Disease
Eosinophilic-Esophagitis
Multiple Myeloma
Nasal Polyps
Neurological Disorders
Prurigo-Nodularis
Rare Diseases

Atopic Dermatitis

Cutting Edge Science
Innovation

Cardiovascular
Atherothrombosis
Dyslipidemia
Hypertension
Thrombosis

Diabetes
Cutting Edge Science

Multiple Sclerosis

Cutting Edge Science
Innovation
2024
2025

Vaccines
Influenza
RSV
Mass Gathering

Patient Support
Atopic Dermatitis
Cardiovascular
Diabetes
Rare Diseases

Products
Adacel®
Cerezyme®
Lemtrada®
Myozyme®
Renvela®
Tavanic®
Xatral®

Aubagio®
Aubagio vs Ofatumumab

Beyfortus®
International Recommendation
Conferences
Real World Evidence
Clinical Experience

Clexane®
Surgical Patients
Hemodialysis

Dupixent®
Atopic Dermatitis

Fabrazyme®
Quantifying the Effect of Fabrazyme
Canadian Fabry Disease Initiative
Long Term Renal Function

Plavix®
Tolerability

Praluent®

It’s Praluent of Course
MACE Reduction
Mortality Reduction
Patient Friendly
Ticks All the Boxes

Soliqua®
For a Peaceful Ramadan
Soli-Simplify Study
Soliqua SoliD®
Soliqua Easy Start®
Soliqua Guidelines®
Soliqua Data Set®
Soliqua Simplicity®
Soliqua Safety®
Soliqua®

Toujeo®
Toujeo for a Peaceful Ramadan
Wall of Evidence
How to Start

Toujeo T1DM
OneCare
Edition Junior
UltraFlexi-1
Type-1 Meta Analysis
Guidelines

Toujeo T2DM
Deliver-G
Guidelines

Toujeo Innovation
Toujeo Upgrade to Win

Login
Registration

Real world evidence

Campus

Back to top

Legal notice Cookie policy Privacy policy Sitemap Change country

© Sanofi 2004- - All rights reserved

MAT-BH-2100734/V7/MAR2024

SANOFI, Level 3, One JLT, Jumeirah Lake Towers (JLT), DMCC, PO Box 53899, Dubai, UAE,

Tel.: +971 4 550 3600 | Fax: +971 4 5521050

For further medical information for all Gulf countries, please contact: +971 45 50 38 63
or email: medical-information.gulf@sanofi.com

To report an adverse event: please call: +971 561747001 or Email: Gulf.pharmacovigilance@sanofi.com
To report any product technical complaints, kindly contact Email: quality.greatergulf@sanofi.com

leave-site-modal-text

YOU WILL NOW BE LEAVING THE SITE

By clicking on this link, you will be leaving the Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but its own.